Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Tango Therapeutics (TNGX) over the last 5 years, with Q2 2025 value amounting to $110.5 million.

  • Tango Therapeutics' Shares Outstanding (Diluted Average) rose 170.02% to $110.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $110.5 million, marking a year-over-year increase of 170.02%. This contributed to the annual value of $109.2 million for FY2024, which is 1549.53% up from last year.
  • Per Tango Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $110.5 million for Q2 2025, which was up 170.02% from $110.3 million recorded in Q1 2025.
  • Tango Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $110.5 million for Q2 2025, and its period low was $48.5 million during Q2 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $88.4 million (2023), whereas its average is $91.5 million.
  • In the last 5 years, Tango Therapeutics' Shares Outstanding (Diluted Average) surged by 8102.15% in 2022 and then surged by 58.61% in 2023.
  • Tango Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $62.1 million in 2021, then surged by 41.4% to $87.8 million in 2022, then rose by 7.69% to $94.6 million in 2023, then rose by 15.5% to $109.2 million in 2024, then rose by 1.2% to $110.5 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $110.5 million for Q2 2025, versus $110.3 million for Q1 2025 and $109.2 million for Q4 2024.